'Godzilla' fat jab retatrutide sheds 20% of body fat in months

Retatrutide Achieves 25% Average Weight Loss in Eli Lilly Phase 2 Trial

A new Eli Lilly drug, retatrutide, achieved striking 25% average weight loss in a Phase 2 trial by targeting three hormones simultaneously. It outperformed current therapies, improved metabolic markers, and showed manageable side effects. Larger Phase 3 trials are now underway.

New weight loss drug Retatrutide leads to dramatic results in trials

'Godzilla' fat jab retatrutide sheds 20% of body fat in months

A new 'Godzilla' fat-jab could rival Mounjaro, helping users shed a fifth of their body weight, while improving blood pressure and cholesterol, research has found.

Triple-Action Weight-Loss Drug Shows Promise for Heart Health

Retatrutide, a first-of-its-kind drug, improved weight, blood sugar and cardiovascular risk markers in Type 2 diabetes patients.

‘Godzilla’ of weight-loss drugs could provide other important health benefits

The ‘Godzilla’ of weight-loss drugs could help improve blood sugar levels, reduce inflammation and cut a person’s body weight by a quarter, according to the largest study of its kind. Retatrutide mimics three key gut hormones that help control appetite, blood sugar and metabolism: GLP-1, GIP and…